Research programme: JAK3 kinase inhibitors - Novartis

Drug Profile

Research programme: JAK3 kinase inhibitors - Novartis

Latest Information Update: 13 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytopia Research
  • Developer Novartis
  • Class Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autoimmune disorders; Transplant rejection

Most Recent Events

  • 13 Jul 2010 Preclinical development is ongoing in Switzerland
  • 01 Feb 2010 Cytopia has been acquired by YM BioSciences and is now called YM BioSciences Australia
  • 04 Jun 2006 Cytopia has signed a global licence and research and development collaboration with Novartis concerning this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top